Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Change in Account Payables of $10000.0 for Q1 2026, down 99.47% year-over-year from $1.9 million in Q1 2025, and down 96.36% quarter-over-quarter from $275000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Change in Account Payables history runs 6 years deep, the most recent figure standing at $10000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 99.47% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at -$1.3 million (up 92.27% YoY), while the FY2025 annual figure was $580000.0, up 103.04% from the prior year.
- Change in Account Payables for Q1 2026 stood at $10000.0, down from $275000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $15.8 million in Q4 2023, with the low at -$18.4 million in Q3 2023.
- The 5-year median for Change in Account Payables is -$33000.0 (2025), against an average of -$45647.1.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables surged 2736.16% in 2022, then slumped 1570.57% in 2023.
- Amylyx Pharmaceuticals' Change in Account Payables stood at -$800000.0 in 2022, then jumped by 2077.5% to $15.8 million in 2023, then slumped by 90.7% to $1.5 million in 2024, then slumped by 81.32% to $275000.0 in 2025, then slumped by 96.36% to $10000.0 in 2026.
- Business Quant data shows AMLX's Change in Account Payables at $10000.0 in Q1 2026, $275000.0 in Q4 2025, and -$33000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.29 Bn | 4.29 Bn | - | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 275,000.00 |
| Dec 31, 2025 | 275,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -1.53 Mn |
| Jun 30, 2025 | -1.53 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -16.44 Mn |
| Jun 30, 2024 | -16.44 Mn |
| Mar 31, 2024 | -652,000.00 |
| Mar 31, 2024 | -652,000.00 |